Literature DB >> 25098059

First cancer statistics report from Hazara division.

Sheraz Ahmad, A Nadim Qureshi, Abida Kazmi, Ahsan Rasool, Mahwish Gul, Muhammad Ashfaq, Laila Batool, Raana Abdur Rehman, Jawad Ahmad.   

Abstract

BACKGROUND: 'Cancer' is on rise globally. Cancer registry is vital for policy making, resource allocation, progress tracking and overall cancer control. In Pakistan, cancer prevention, screening and standardised clinical trials, as well as quality assurance through surveillance are badly hampered due to the lack of a National Cancer Registry. For Pakistan a well-integrated system of Cancer Registry is need of the day.
METHODS: This retrospective study was conducted on the hospital records at the Oncology Department of Ayub Teaching Hospital, Abbottabad from year 2007-12. Data were collected tIhrough a standard data capture form with a final figure of 555 patients. The malignancies were diagnosed clinically and histopathologically at different laboratories of Pakistan.
RESULTS: Among these cases, 54.08% were male and 45.92% female. Incidence of cancer in patients below 14 years age was 8.47% and 91.53% above 14 years. Majority (31.95%) cases were from Mansehra followed by Abbottabad with 27.08% and Haripur 14.26% cases. Leukaemias were at top with 15.14% cases followed by breast carcinoma (13.69%), Lymphomas (12.07%), ovarian carcinomas (8.65%), and gastric carcinoma and skin cancers with 2.70% each. Among men, the highest incidence was of Hodgkin's lymphoma (14.9%) followed by lymphocytic Ieukaemia (14.3%). Prostate cancer was seen in 8.3% male patients. Another 5.7% patients had lung cancer. In women, the highest incidence was carcinoma breast (19.7%) followed by ovarian carcinoma (13.4%), leukaemia (9.7%), and Hodgkin's lymphoma (4.3%).
CONCLUSION: A variety of cancers are prevalent in the indigent population. Record-keeping in wards is sub-optimal. Commonest cancers in the area have slight differences with rest of the country.

Entities:  

Mesh:

Year:  2013        PMID: 25098059

Source DB:  PubMed          Journal:  J Ayub Med Coll Abbottabad        ISSN: 1025-9589


  5 in total

1.  Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.

Authors:  Xiao-Xiu Huang; Feng-Feng Xie; Li-Jiao Hou; Xiu-Xiu Chen; Rong-Ying Ou; Jiang-Tao Yu; Jian-Ge Qiu; Wen-Ji Zhang; Qi-Wei Jiang; Yang Yang; Di-Wei Zheng; Yao Chen; Jia-Rong Huang; Kun Wang; Meng-Ning Wei; Wen-Feng Li; Zhi Shi; Xiao-Jian Yan
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

2.  Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.

Authors:  Xiu-Xiu Chen; Feng-Feng Xie; Xiu-Jie Zhu; Feng Lin; Shi-Shi Pan; Li-Hua Gong; Jian-Ge Qiu; Wen-Ji Zhang; Qi-Wei Jiang; Xiao-Long Mei; You-Qiu Xue; Wu-Ming Qin; Zhi Shi; Xiao-Jian Yan
Journal:  Oncotarget       Date:  2015-06-20

3.  Cancer prevalence in Pakistan: meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country.

Authors:  Romana Idrees; Saira Fatima; Jamshid Abdul-Ghafar; Ahmad Raheem; Zubair Ahmad
Journal:  World J Surg Oncol       Date:  2018-07-05       Impact factor: 2.754

4.  Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients.

Authors:  Na Zhang; Yangyang Wu; Yifan Wu; Lihong Wang; Jingfei Chen; Xiaosa Wang; Louisa S Chard Dunmall; Zhenguo Cheng; Yaohe Wang
Journal:  Cells       Date:  2022-07-15       Impact factor: 7.666

5.  Institutional-based tumor registry of hematopoietic malignancies: A 4 years' preliminary report from Karachi.

Authors:  Sadia Sultan; Syed Mohammed Irfan; Navaira Ali; Neesha Nawaz
Journal:  J Lab Physicians       Date:  2018 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.